Validation of Efficacy for Second Suicide-Associated Psychiatric Indication Supports Push for Clinical Entry of Novel Brain-Healing Stem Cell Type
Therapeutic Solutions International announced positive data and filing of a patent covering the use of CampbellCell for treatment of Bipolar Disorder by the Company’s suicide prevention based spin-off Campbell Neurosciences.
In a series of animal experiments using an established animal model of bipolar disorder, superior inhibition of behavioral abnormality as measured in the “Open Field Test”, as well as reduction in brain inflammation was observed in animals treated with CampbellCell as compared to control stem cells. Furthermore, it was found that protection from behavioral abnormalities could be transferred to naïve mice by T cell infusions, indicating that an immunological effect was present.
“We initially demonstrated a biological basis to suicidality by our clinical trial demonstrating validity of the Campbell Score1,2. We subsequently demonstrated that the CampbellCell, which possesses potent regenerative and anti-inflammatory activities is capable of treating Schizophrenia in animal models3. Today we disclosed that the CampbellCell is also capable of treating bipolar disorder models,” said Kalina O’Connor, President, and CEO of Campbell Neurosciences. “We are advancing toward clinical trials in both Schizophrenia and Bipolar Disorder, which we believe will position the Company as the first to merge psychiatry with regenerative medicine.”
“Having used various stem cell therapies in my practice, including JadiCell, for which we are currently running a Phase III clinical trial, I have seen the potent effects this regenerative approach can have on many branches of medicine,” said Dr. James Veltmeyer, Chief Medical Officer of the Company, and co-inventor of the patent. “I am proud to be working with Ms. O’Connor and her team at Campbell Neurosciences in creating, what I believe to be, the first science-based approach to diagnosing and treating suicide as a disease and not a choice.”
Bipolar Disorder and Schizophrenia are recognized as major contributors to suicide and have been associated with various immunological abnormalities. For a review of the inflammatory nature of suicide-associated mental illness, the reader is referred to a paper published by Ms. O’Conner4.
“Campbell Neurosciences was capable of successfully raising capital, running two clinical trials for its diagnostic platform, and now has late preclinical data on two significant suicide-associated indications. This speaks volumes for our model of incubating technologies and spinning them off,” said Timothy Dixon, President, and CEO of Therapeutic Solutions International and co-inventor. “Through cross-fertilizing and sharing resources and talent between our companies, I am excited to see acceleration in clinical development and hopefully new treatments for this immensely important and underserved area of mental health.”
About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.
1 https://www.clinicaltrials.gov/ct2/show/NCT04606875
2 Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Clinical Trial Results for Campbell Score Blood Based Suicide Prediction | BioSpace
3 Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Preclinical Safety and Efficacy Data Using CampbellCell™ for Treatment of Schizophrenia (yahoo.com)
4 Suicide: An Immunological Disorder? by Kalina O'Connor :: SSRN
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005457/en/
Contacts
Timothy G. Dixon
ir@tsoimail.com
